Christopher F Bell1, Matthew Lau2,3, Melody Lee2, Christine Poulos4. 1. GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, USA. christopher.f.bell@gsk.com. 2. GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, USA. 3. Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA. 4. RTI Health Solutions, Research Triangle Park, NC, USA.
Abstract
INTRODUCTION/ OBJECTIVES: Multiple modes of administration are available for systemic lupus erythematosus (SLE) treatments. This study examined patient and physician characteristics associated with the choice of weekly subcutaneous (SC) injection or monthly intravenous (IV) infusion for an unspecified SLE treatment. METHODS: This was a cross-sectional, US web-based survey using a direct elicitation, stated-preference methodology (HO-16-16706). Two hundred patients and 200 physicians were asked to choose between IV or SC administration in a hypothetical scenario. Pairwise and multivariate analyses estimated the odds ratio (OR) for the likelihood of choosing SC over IV for respondent characteristics. RESULTS: Among patients, taking non-steroidal anti-inflammatory drugs increased the likelihood of choosing SC injection (OR 3.884), whilst having SLE-related skin problems, a fear of needles or self-injection, and never needing help around the house decreased the likelihood (OR 0.28, 0.13, 0.12, respectively; all p ≤ 0.05). Among physicians, > 95% recommended SC injection for patients who live or work far from an infusion center, prefer SC administration, and never or rarely miss medication doses. Physician characteristics including age and treatment practice also influenced choice. CONCLUSIONS: Patient and physician characteristics influence choice of SC versus IV therapy for SLE. These findings might inform shared decision-making, which could lead to improved patient outcomes. Key Points • Data regarding patient and physician preference for different modes of administration of SLE therapy are sparse. • This cross-sectional, US web-based study showed that patient and physician characteristics influence choice of SC versus IV therapy for SLE. • A degree of disconnect exists between how factors influence patients' choice and how those characteristics influence physicians' choice of SLE treatment mode of administration. • The findings from this study might inform shared decision-making, which could improve alignment between treatment choice and patient preferences, treatment satisfaction, adherence, and improved patient outcomes.
INTRODUCTION/ OBJECTIVES: Multiple modes of administration are available for systemic lupus erythematosus (SLE) treatments. This study examined patient and physician characteristics associated with the choice of weekly subcutaneous (SC) injection or monthly intravenous (IV) infusion for an unspecifiedSLE treatment. METHODS: This was a cross-sectional, US web-based survey using a direct elicitation, stated-preference methodology (HO-16-16706). Two hundred patients and 200 physicians were asked to choose between IV or SC administration in a hypothetical scenario. Pairwise and multivariate analyses estimated the odds ratio (OR) for the likelihood of choosing SC over IV for respondent characteristics. RESULTS: Among patients, taking non-steroidal anti-inflammatory drugs increased the likelihood of choosing SC injection (OR 3.884), whilst having SLE-related skin problems, a fear of needles or self-injection, and never needing help around the house decreased the likelihood (OR 0.28, 0.13, 0.12, respectively; all p ≤ 0.05). Among physicians, > 95% recommended SC injection for patients who live or work far from an infusion center, prefer SC administration, and never or rarely miss medication doses. Physician characteristics including age and treatment practice also influenced choice. CONCLUSIONS:Patient and physician characteristics influence choice of SC versus IV therapy for SLE. These findings might inform shared decision-making, which could lead to improved patient outcomes. Key Points • Data regarding patient and physician preference for different modes of administration of SLE therapy are sparse. • This cross-sectional, US web-based study showed that patient and physician characteristics influence choice of SC versus IV therapy for SLE. • A degree of disconnect exists between how factors influence patients' choice and how those characteristics influence physicians' choice of SLE treatment mode of administration. • The findings from this study might inform shared decision-making, which could improve alignment between treatment choice and patient preferences, treatment satisfaction, adherence, and improved patient outcomes.
Authors: Haiyan Qu; Richard M Shewchuk; Graciela Alarcón; Liana Fraenkel; Amye Leong; Maria Dall'Era; Jinoos Yazdany; Jasvinder A Singh Journal: Arthritis Care Res (Hoboken) Date: 2016-12 Impact factor: 4.794
Authors: Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven Journal: Arthritis Rheum Date: 2011-12
Authors: Kevin P Baker; Bryan M Edwards; Sarah H Main; Gil H Choi; Ruth E Wager; Wendy G Halpern; Patrick B Lappin; Todd Riccobene; Donara Abramian; Les Sekut; Bonnie Sturm; Carol Poortman; Ralph R Minter; Claire L Dobson; Elizabeth Williams; Sara Carmen; Rodger Smith; Viktor Roschke; David M Hilbert; Tristan J Vaughan; Vivian R Albert Journal: Arthritis Rheum Date: 2003-11
Authors: William Stohl; Andreas Schwarting; Masato Okada; Morton Scheinberg; Andrea Doria; Anne E Hammer; Christi Kleoudis; James Groark; Damon Bass; Norma Lynn Fox; David Roth; David Gordon Journal: Arthritis Rheumatol Date: 2017-04-07 Impact factor: 10.995
Authors: Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: Philip J Smith; Lisa Critchley; Daniel Storey; Belle Gregg; June Stenson; Andrew Kneebone; Tracy Rimmer; Stevena Burke; Shamas Hussain; Wan Yi Teoh; Stephan Vazeille; Solange Serna; Alan Steel; Edmund Derbyshire; Paul Collins; Martyn Dibb; Paul Flanagan; Christopher Probert; Ajay M Verma; Sreedhar Subramanian Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020